Avalo Therapeutics AVTX Business Segments — Nonclinical expenses

Similar metrics at other companies

VIRReportable Segment — Clinical costs

$26.13M+26.8%

RYTMSingle reportable segment — Preclinical, clinical and development expense

$18.51M-7.3%

BCAXReportable Segment — Clinical operations and development

$23.21M+24.4%

INBXReportable Segment — Research And Development Expense, Clinical Trials

$9.18M-30.8%

VRDNReportable Segment — Segment research and development expense

$71.74M+1.0%

RXRXReportable Segment — Clinical development

$6.57M-37.8%

Questions, answered.

What is Avalo Therapeutics's business segments — nonclinical expenses?

Avalo Therapeutics (AVTX) reported business segments — nonclinical expenses of $419K in Q1 2026.

How has Avalo Therapeutics's business segments — nonclinical expenses changed year-over-year?

Avalo Therapeutics's business segments — nonclinical expenses increased by 404.8% year-over-year, from $83K to $419K.

What is the long-term trend for Avalo Therapeutics's business segments — nonclinical expenses?

Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — nonclinical expenses has grown at a -10.5% compound annual growth rate (CAGR), from $1.03M to $825K.

What does business segments — nonclinical expenses mean?

Represents the costs associated with early-stage research activities, including laboratory studies and animal testing conducted prior to human clinical trials. These expenditures are critical for assessing the safety and efficacy profiles of drug candidates before regulatory approval for human testing. Monitoring these costs helps investors understand the company's investment in the foundational stages of its drug development pipeline.